Concepedia

Mark Donovan

MD

Statistics

Publications

15

Citations

2.8K

H-Index

14

Active since

2007

Affiliations

Bristol-Myers Squibb (United States)(Current)

Sorbonne Université

AstraZeneca (United States)

Bristol-Myers Squibb (Sweden)

McMaster University

Mark Donovan is an author at Bristol-Myers Squibb (United States) specializing in medicine, clinical pharmacology, and pharmacology.

Publications per year

2007–2023

15

Publications

15

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

Barry M. Massie, Peter E. Carson, John J.V. McMurray et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

, , +12

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

Robert Frederich, John H. Alexander, Fred T. Fiedorek et al. · Postgraduate Medicine · 2010 · 218 citations

, , +15

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

Anthony Barnett, B Charbonnel, Mark Donovan et al. · Current Medical Research and Opinion · 2012 · 162 citations

, , +17

Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial

Robert S. McKelvie, Michel Komajda, John J.V. McMurray et al. · Journal of Cardiac Failure · 2009 · 64 citations

, , +12

Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors

Lillian L. Siu, Howard A. Burris, Dung T. Le et al. · Cancer Research · 2018 · 64 citations

, , +17

1–5 of 15